Platelet Aggregation Inhibitors
Tech ID: 18905 / UC Case 2001-089-0
Background
Thrombin is an enzyme in the blood that plays a key role in platelet formation during injury. While blood coagulation is essential for a surface wound, platelet activation underlies various pathological situations such as unstable angina pectoris, myocardial infarction and stroke. Thrombin is mediated by protease activated receptor-1 (PAR-1) which is expressed in the nervous system and in platelets. Once activated by thrombin, PAR-1 induces rapid and dramatic changes in cell morphology that is controlled by a series of localized ATP-dependent reactions.
Technology Description
Researchers at the University of California have discovered specific creatine kinase inhibitors that inhibit thrombin-induced aggregation of platelets. These creatine kinase inhibitors could be used to treat a disease or disorder that is caused by pathological platelet aggregation.
Applications
This treatment has applications both for humans and in veterinary medicine.
Patent Status
| Country | Type | Number | Dated | Case |
| United States Of America | Issued Patent | 6,444,695 | 09/03/2002 | 2001-089 |
Other Information
Categorized As
Related cases
2001-089-0
Contact
Maria Tkachuk / mtkachuk@uci.edu / tel: View Phone Number. Please reference Tech ID #18905.
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- ADP Glucose Receptor as a Target for Disorders Involving Platelet Aggregation
- New Chemical Entities for the Treatment and Prevention of Diabetes and Metabolic Disorders
- Transgenic Mouse Model for Screening Analgesic Agents
- Neuropeptide S (NPS) as a Treatment for Anxiety, Sleep Disorders, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, and Asthma
- Melanin Concentrating Hormone Receptor Small Molecule Antagonists for the Treatment of Obesity and Related Metabolic Disorders